Literature DB >> 9440581

The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy.

D C Rhew1, D Hackner, L Henderson, A G Ellrodt, S R Weingarten.   

Abstract

OBJECTIVE: To assess the benefit of in-hospital observation in "low-risk" patients with community-acquired pneumonia.
DESIGN: Retrospective review of data from a prospective study.
SETTING: Teaching community hospital. PATIENTS: We studied 717 consecutive, adult patients admitted to the hospital for pneumonia. MEASUREMENTS AND
RESULTS: One hundred forty-five patients were classified at low-risk for complications using previously studied criteria; 144 (99%) charts were available for review. Two patients had "obvious reasons for continued hospitalization" on the day of antibiotic conversion and were excluded. One hundred two patients were observed, and 40 were not observed in-hospital after switch to oral antibiotics. No patient from either group required medical intervention within 24 h after hospital discharge. Five "observed" patients (5%, 95% confidence interval [CI], 2 to 11%) returned to the emergency department, three (3%; 95% CI, 0 to 9%) with respiratory complaints. Two (2%; 95% CI, 0 to 7%) "observed" patients were admitted to the hospital with recurrent pneumonia. One (3%; 95% CI, 0 to 13%) "not observed" patient returned to the emergency department with a nonrespiratory complaint and was not admitted. No patient from either group died within 30-day clinical follow-up. The length of stay for the "observed" and "not observed" groups was 98+/-33 h and 83+/-49 h, respectively. The difference in length of stay was 15 h (95% CI, 3 to 27).
CONCLUSIONS: In-hospital observation for low-risk patients admitted with community-acquired pneumonia after switch from parenteral to oral antibiotics is of limited benefit, and elimination of this practice could potentially reduce length of stay by almost 1 day per patient. This could translate into a cost savings of $57,200 for the 22-month study period. These results require prospective validation in a larger study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9440581     DOI: 10.1378/chest.113.1.142

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Community-Acquired Pneumonia: An Overview.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  Clinical and economic impact of rapid reporting of bacterial identification and antimicrobial susceptibility results of the most frequently processed specimen types.

Authors:  A Galar; J R Yuste; M Espinosa; F Guillén-Grima; S Hernáez-Crespo; J Leiva
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-08       Impact factor: 3.267

4.  What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?

Authors:  E A Halm; G E Switzer; B S Mittman; M B Walsh; C C Chang; M J Fine
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

Review 5.  Community-acquired pneumonia in the elderly: a practical guide to treatment.

Authors:  D Lieberman; D Lieberman
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

Review 6.  Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.

Authors:  Joseph L Kuti; Blair Capitano; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 7.  Community-acquired pneumonia.

Authors:  Thomas M File
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.